 | Up a level |
Krudewig, J; Baumann, U; Bernuth von, H; Borte, M; Burkhard-Meier, U; Dueckers, G; Foerster-Waldl, E; Franke, K; Habermehl, P; Hönig, M; Kern, W; Kösters, K; Kugel, K; Lehrnbecher, T; Liese, J; Marks, R; Müller, G A; Müller, R; Nadal, D; Peter, H-H; ... (2012). [Interdisciplinary AWMF guideline for the treatment of primary antibody deficiencies]. Klinische Pädiatrie, 224(6), pp. 404-15. Stuttgart: Thieme 10.1055/s-0032-1323837
Stein, MR; Nelson, RP; Church, JA; Wassermann, RL; Borte, M; Vermylen, C; Pichler, WJ (2009). Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficienceis. Journal of clinical immunology, 29(1), pp. 137-144. New York, N.Y.: Springer 10.1007/s10875-008-9231-2
Misbah, S; Sturzenegger, M H; Borte, M; Shapiro, R S; Wasserman, R L; Berger, M; Ochs, H D (2009). Subcutaneous immunoglobulin: opportunities and outlook. Clinical and experimental immunology, 158 Suppl 1(Suppl 1), pp. 51-59. Oxford: Blackwell Scientific Publications 10.1111/j.1365-2249.2009.04027.X
Borte, M; Horneff, G; Kempf, Christoph; Kaise, R; Korinthenberg, R; Körholz, D; Mauz-Körholz, C; Nadal, D; Niggemann, B; Roos, R; Späth, Peter; Wahn, V; Wehmeier, A; Zepp, F; Zielen, S (2007). Herstellung von intravenös verabreichbaren Immunglobulinen und Pathogensicherheit. In: Wahn, Volker (ed.) Klinischer Einsatz von Immunglobulinen (pp. 28-47). Bremen et al.: UNI-MED
